A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy
Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jun 8, 2015
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool that uses small molecules called microRNAs to help decide whether patients with stage II colon cancer should receive additional treatment called adjuvant chemotherapy after their surgery. The goal is to find out if this tool can better identify which patients will benefit from chemotherapy compared to traditional methods. Participants in the study will be randomly assigned to be evaluated either by the new microRNA tool or by standard tests to see who should receive chemotherapy. Researchers will observe how long patients remain cancer-free and their overall survival rates.
To be eligible for the trial, participants must be adults diagnosed with stage II colon cancer who have not received any cancer treatments before their surgery. They should also be in fairly good health, with a specific score that indicates their ability to perform daily activities. However, individuals with serious health conditions or those who are pregnant cannot participate. The trial is not yet recruiting patients, but it aims to help doctors make better decisions about chemotherapy for patients with this type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The informed consent has been obtained from the patient.
- • With confirmed diagnosis of stage II colon cancer.
- • With moderate/good ECOG health rating (PS): 0-1 score.
- • The patient receive no anti-cancer treatment before primary surgery.
- • The patient receive radical operation for colon cancer with negative margin.
- Exclusion Criteria:
- • With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
- • With bad compliance or contraindication to enrollment.
- • Pregnant woman or lactating woman.
- • With contraindication to receive adjuvant chemotherapy.
About First Affiliated Hospital, Sun Yat Sen University
The First Affiliated Hospital of Sun Yat-sen University is a prestigious medical institution located in Guangzhou, China, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. As a leading teaching hospital, it combines clinical excellence with academic rigor, facilitating a wide range of clinical trials across various specialties. The hospital is dedicated to improving health outcomes and contributing to medical knowledge, leveraging its state-of-the-art facilities and a team of highly qualified professionals to conduct high-quality research that adheres to international standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Wu Song, MD
Study Director
First Affiliated Hospital, Sun Yat-Sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials